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Long-Term Systemic Myostatin Inhibition via Liver-Targeted Gene
Transfer in Golden Retriever Muscular Dystrophy
Abstract
Duchenne muscular dystrophy (DMD) is a lethal, X-linked recessive disease affecting 1 in 3,500 newborn
boys for which there is no effective treatment or cure. One novel strategy that has therapeutic potential for
DMD is inhibition of myostatin, a negative regulator of skeletal muscle mass that may also promote fibrosis.
Therefore, our goal in this study was to evaluate systemic myostatin inhibition in the golden retriever model of
DMD (GRMD). GRMD canines underwent liver-directed gene transfer of a self-complementary adeno-
associated virus type 8 vector designed to express a secreted dominant-negative myostatin peptide (n =4) and
were compared with age-matched, untreated GRMD controls (n =3). Dogs were followed with serial
magnetic resonance imaging (MRI) for 13 months to assess cross-sectional area and volume of skeletal
muscle, then euthanized so that tissue could be harvested for morphological and histological analysis. We
found that systemic myostatin inhibition resulted in increased muscle mass in GRMD dogs as assessed by
MRI and confirmed at tissue harvest. We also found that hypertrophy of type IIA fibers was largely
responsible for the increased muscle mass and that reductions in serum creatine kinase and muscle fibrosis
were associated with long-term myostatin inhibition in GRMD. This is the first report describing the effects of
long-term, systemic myostatin inhibition in a large-animal model of DMD, and we believe that the simple and
effective nature of our liver-directed gene-transfer strategy makes it an ideal candidate for evaluation as a novel
therapeutic approach for DMD patients.
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Abstract
Duchenne muscular dystrophy (DMD) is a lethal, X-linked recessive disease affecting 1 in 3,500 newborn boys
for which there is no effective treatment or cure. One novel strategy that has therapeutic potential for DMD is
inhibition of myostatin, a negative regulator of skeletal muscle mass that may also promote fibrosis. Therefore,
our goal in this study was to evaluate systemic myostatin inhibition in the golden retriever model of DMD
(GRMD). GRMD canines underwent liver-directed gene transfer of a self-complementary adeno-associated virus
type 8 vector designed to express a secreted dominant-negative myostatin peptide (n = 4) and were compared
with age-matched, untreated GRMD controls (n = 3). Dogs were followed with serial magnetic resonance im-
aging (MRI) for 13 months to assess cross-sectional area and volume of skeletal muscle, then euthanized so that
tissue could be harvested for morphological and histological analysis. We found that systemic myostatin inhi-
bition resulted in increased muscle mass in GRMD dogs as assessed by MRI and confirmed at tissue harvest. We
also found that hypertrophy of type IIA fibers was largely responsible for the increased muscle mass and that
reductions in serum creatine kinase and muscle fibrosis were associated with long-term myostatin inhibition in
GRMD. This is the first report describing the effects of long-term, systemic myostatin inhibition in a large-animal
model of DMD, and we believe that the simple and effective nature of our liver-directed gene-transfer strategy
makes it an ideal candidate for evaluation as a novel therapeutic approach for DMD patients.
Introduction
Duchenne muscular dystrophy (DMD) is a lethal,X-linked recessive disease affecting one in 3,500 newborn
boys that results from a mutation in the dystrophin gene
(Emery, 2002). Thousands of mutations in the 79-exon dystro-
phin gene have been reported,with themost severe cases being
associated with disruption of the reading frame and loss of
functional dystrophin production (Aartsma-Rus et al., 2006).
Boys typically present with symptoms of muscle weakness by
age five, become wheelchair-bound by early to mid teens, and
die from respiratory failure or cardiomyopathy in their late
teens to early twenties (Muntoni et al., 2003; Tyler, 2003; Wang
et al., 2009). Patients with dystrophin mutations that maintain
the reading frame and produce truncated but partially func-
tional dystrophin exhibit the milder phenotype of Becker
muscular dystrophy (Aartsma-Rus et al., 2006). Unfortunately,
no effective therapy or cure exists for DMD, and novel thera-
peutic strategies are in need of development.
Gene therapy is one approach that has potential as a novel
treatment for DMD (Wang et al., 2009). The majority of gene-
therapy investigations have focused on strategies aimed
at restoring dystrophin expression or increasing muscle
mass and have been performed in either the mdx mouse
(Sicinski et al., 1989) or canine X-linked muscular dystrophy
(Valentine et al., 1988; Sharp et al., 1992) models of DMD.
Restoration of dystrophin expression has been accomplished
by gene transfer of mini- and microdystrophin constructs in
dystrophic mice (Harper et al., 2002; Gregorevic et al., 2004;
Liu et al., 2005), dogs (Wang et al., 2007; Kornegay et al., 2010),
and humans (Miyagoe-Suzuki and Takeda, 2010), as well as
by induction of exon skipping in dystrophic mice (Goyenvalle
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et al., 2004; Denti et al., 2006, 2008), dogs (Yokota et al., 2009),
and humans (Miyagoe-Suzuki and Takeda, 2010; Moulton
and Moulton, 2010; Partridge, 2010). Proof-of-principle studies
demonstrating successful gene transfer of microdystrophin
(Rodino-Klapac et al., 2010) and successful induction of exon
skipping (Moulton and Moulton, 2010) have also been per-
formed in healthy nonhuman primates (NHPs).
A second gene therapy–based strategy currently under in-
vestigation for the treatment of DMD is aimed at targeting the
myostatin pathway to increase muscle mass and potentially
decrease fibrosis and improve regeneration. Myostatin, a
member of the transforming growth factor-b (TGF-b) family of
proteins, is a negative regulator of skeletal muscle mass
(McPherron et al., 1997; Lee, 2004). Indeed, loss-of-function
mutations leading to increased muscle mass have been de-
scribed in several species (Lee, 2007b), including humans
(Schuelke et al., 2004), and investigators using gene transfer
approaches have demonstrated that inhibition of myostatin
can increase muscle mass and attenuate the dystrophic phe-
notype in mdx mice (Qiao et al., 2008; Morine et al., 2010a,b).
Pharmacological and/or genetic targeting of the myostatin
pathway has also been evaluated in dystrophic mice (Bog-
danovich et al., 2002, 2005, 2008; Wagner et al., 2002; Pistilli
et al., 2011); however, the one human trial targeting a number
of muscular dystrophies, including DMD, with an inhibitory
myostatin antibody was not conclusive (Wagner et al., 2008).
Although proof-of-principle experiments in canines (Qiao
et al., 2009) and NHPs (Kota et al., 2009) have demonstrated
increased skeletal muscle mass following gene transfer of
myostatin inhibitors, evaluation of myostatin inhibition in
large-animal models of DMD has not yet been performed.
Therefore, our goal in this study was to evaluate systemic
myostatin inhibition in the golden retriever model of DMD
(GRMD). GRMD canines underwent liver-directed gene
transfer of a self-complementary adeno-associated virus (AAV)
type 8 (scAAV8) vector designed to express a secreted domi-
nant-negative myostatin (dnMSTAT) peptide, a strategy that
we previously evaluated in the mdx mouse (Morine et al.,
2010a). Dogs were followed for 13 months following gene
transfer. We found that systemic myostatin inhibition resulted
in increased muscle mass in GRMD canines as assessed by
magnetic resonance imaging (MRI) and confirmed at tissue
harvest. We also found that hypertrophy of type IIA fibers was
largely responsible for the increased muscle mass and that re-
ductions in serum creatine kinase (CK) and muscle fibrosis
were associatedwith long-termmyostatin inhibition inGRMD.
Materials and Methods
Vector design and production
scAAV8 vectors were produced according to the previously
described pseudotyping protocol by the Vector Core of the
Children’s Hospital of Philadelphia (Herzog et al., 1999). In
brief, recombinant AAV genomes containing AAV2 inverted
terminal repeats (ITRs) were packaged by triple transfection of
293 cells with a cis-plasmid containing the enhanced green
fluorescent protein (EGFP) transgene, an adenovirus helper
plasmid, and a chimeric trans-plasmid containing theAAV2 rep
gene fused to the capsid gene of the AAV6. Self-complementary
vectors contained a mutation in the termination sequence of
the 5’ ITR to allow synthesis and encapsidation of a dimeric
inverted repeat of the transgene cassette (McCarty et al., 2001).
The scAAV8-TBG-dnMSTAT construct was designed to
express the secreted canine myostatin Belgian Blue inhibitory
peptide (Kambadur et al., 1997) containing a D76A mutation
that confers protease resistance (Wolfman et al., 2003) under
control of the liver-specific thryroid-hormone binding glob-
ulin (TBG) promoter (Bell et al., 2011).
Animal use and vector delivery protocol
All animals were handled in compliance with National
Institutes of Health and institutional guidelines that were
approved by the Institutional Animal Care and Use Com-
mittee of the University of Pennsylvania. A total of nine ca-
nines were used in this study. At the time of treatment, dogs
were 9–10 months old and weighed 14–19 kg. The scAAV8-
TBG-dnMSTAT vector was tested in two normal canines
prior to its use in GRMD canines. One normal canine re-
ceived 1012 genome copies (gc)/kg vector via hepatic artery
infusion as previously described (Bell et al., 2011), and one
normal canine received 1012 gc/kg vector via peripheral in-
travenous (IV) infusion (cephalic vein). The remaining dogs
used in the study were GRMD canines, which received either
1.7 · 1012 gc/kg vector (n= 4) via IV infusion or no treatment
(n= 3). Euthanasia occurred 13 months post infusion, at*23
months of age. GRMD canines were produced in a colony at
the University of North Carolina at Chapel Hill and were
cared for according to principles outlined in the National
Institutes of Health Guide for the Care and Use of Labora-
tory Animals. The phenotype was initially determined based
on elevation of serum creatine kinase and confirmed by PCR.
All canines used in this study were screened for the pres-
ence of preexisting neutralizing antibodies (NAbs) against
AAV8. The AAV8 NAb titer for all canines was < 1:20, which
was the lower limit of detection in this assay. Titer was de-
termined by incubating Huh7 cells with serial dilutions of
canine serum and AAV-CMV-EGFP of the serotype in ques-
tion and observing the dilution at which the number of
GFP-positive cells was reduced by 50% compared with
control wells.
RT-PCR analysis
Tissue collected for RT-PCR analysis was snap-frozen in
liquid nitrogen and processed as described previously
(Morine et al., 2010a). Samples were crushed on a mortar and
pestle cooled by dry ice, and total RNA was isolated from
muscle homogenates by RNA TRIzol extraction (Invitrogen,
Carlsbad, CA). One hundred fifty nanograms of RNA from
each sample was subjected to single-strand reverse tran-
scription, and the resulting cDNA was used in a PCR reac-
tion with Taq polymerase (Applied Biosystems, Foster City,
CA). The primers for dnMSTAT were as follows: forward
5¢ GTT-TAG-CTC-TAA-AAT-ACA-ATA-TAA-TA 3¢ and
reverse 5¢ AAC-TTG-TTT-ATT-GCA-GCT-TAT-AAT-G 3¢.
These primers were located within the transgene and SV40
poly(A) tail, respectively, to detect vector sequence specifically.
Vector plasmidwas used as a positive control for these primers.
The primers for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were as follows: forward 5¢ ATG-GTG-AAG-GTC-
GGA-GTC-AAC-GGA-T 3¢ and reverse 5¢ GAA-GAT-GGA-
GAT-GGA-CTT-CCC-GTT-G 3¢. The resulting PCR reactions
were run on a 1.5% agarose gel with ethidium bromide and
visualized under ultraviolet light.
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Western blot analysis
Cardiac biopsies obtained for western blotting were snap-
frozen in liquid nitrogen. Specimens were pulverized, ho-
mogenized in 10 volumes of triple-detergent lysis buffer
[50mM Tris, pH 8.0, 0.1% sodium dodecyl sulfate (SDS),
1.0% Triton X-100, 0.5% deoxycorticosterone, 5mM EDTA,
50mM dithiothreitol (DTT), 0.4 tablet/10ml Complete Pro-
tease Inhibitor (Roche, Indianapolis, IN)], and centrifuged at
13,000 rpm for 5min. Protein concentration of the superna-
tant was then determined using the Bio-Rad Protein Assay
(Bio-Rad, Hercules, CA). Fifty micrograms of each sample
was electrophoresed on a 20% SDS-polyacrylamide gel
(Lonza, Rockland, ME) following the addition of 2· sample
loading buffer (130mM Tris, pH 8.0, 20% glycerol, 4.6% SDS,
2% DTT, 0.02% bromophenol blue) and 5min of denatur-
ation at 100C. Proteins were then transferred to Immobilon-
P (Millipore, Bedford, MA) using the iBlot transfer apparatus
(Invitrogen). The membrane was subsequently blocked with
5% nonfat dry milk in Tris-buffered saline containing 0.05%
Tween 20. Immunoblotting was performed to detect myos-
tatin N-terminus (1:1,000; R&D Systems, Minneapolis, MN).
Detection was performed using the SuperSignal West Pico
Chemiluminescent Substrate Kit (Pierce, Rockford, IL).
Muscle morphology and histology
The tibialis cranialis (TC), extensor digitorum longus (EDL),
gastrocnemius, and flexor digitorum superficialis (FDS) mus-
cles were explanted from the canine and weighed. Muscles
were subsequently embedded in Optimal Cutting Tempera-
ture compound (Sakura Finetek, Torrance, CA) and frozen in
liquid nitrogen–cooled isopentane. Ten-micrometer sections
were cut, and the resulting slides were stored at - 20C.
Immunohistochemistry was used to determine the fiber
sizes, fiber number, and myosin heavy-chain (MHC) com-
position of examined muscles as described previously
(Barton et al., 2002). Sections were blocked in 5% bovine se-
rum albumin (BSA) in phosphate-buffered saline (PBS) and
then incubated overnight in 5% BSA in PBS containing a
rabbit anti-laminin monoclonal antibody diluted 1:100
(Neomarkers, Fremont, CA) and one type-specific MHC
primary antibody (type I, BA-F8, 1:50; type IIA, SC-71, 1:10).
Following washes in PBS, sections were incubated with
secondary antibody (Invitrogen) for 1 hr in the dark at room
temperature. Slides were washed and mounted with Vecta-
shield with 4,6-diamidino-2-phenylindole (DAPI). All images
were captured and processed on a Leitz DMRBE fluorescent
microscope (Leica, Bannockburn, IL) equipped with a Mi-
croMAX digital camera system (Princeton Instruments,
Trenton, NJ). Openlab imaging software (Improvision, Wal-
tham, MA) was used for further analysis.
Trichrome staining was performed to determine the extent
of fibrosis according to the manufacturer’s instructions
(Sigma, St. Louis, MO).
Serum CK
Blood samples were collected at euthanasia, allowed to
clot for 2 hr at room temperature, then centrifuged at 2,000 g
for 20min to isolate serum. Serum was stored at - 80C, and
CK was measured later using the assay manufactured by
Genzyme (Charlottetown, PEI, Canada).
Magnetic resonance imaging
Three-dimensional (3D)-gradient echo (TR, 19.2msec; TE,
2.3msec; flip angle, 30; NEX, 3; slices, 86; slice thickness,
2mm) and fast spin echo (TR, 2 sec; TE, 16, 32, 48, 64msec;
NEX, 3; slices, 24; slice thickness, 2mm) axial images of the
lower hind limbs were acquired using a 1.5T GE scanner
with a wrist volume coil. Each limb was scanned separately.
Dogs were induced with a continuous rate of infusion of
propofol (1.0–2.0mg/min/kg) and fentanyl (0.005mg/kg/
min), with maintenance via propofol (0.2mg/kg/min), fen-
tanyl (0.7 lg/kg/min), and a bolus of cisatracurium (0.1mg/
kg). Respiration, electrocardiogram, O2 saturation, and blood
pressure were monitored.
For analysis, maximal cross-sectional area (CSAmax) was
measured in the medial (MG) and lateral gastrocnemius
(LG), EDL, FDS, and TC of both lower hind limbs using
OsiriX software (v.3.8.1). This was performed using the axial
images of the 3D-gradient echo sequence and manually
tracing the muscles of numerous slices (minimum of six). The
CSAmax was defined as the average of the largest region of
interest (ROI) of a muscle in an axial image and the ROI in
the adjacent proximal and distal images, resulting in an av-
erage of three slices. As the entire anterior compartment (AC)
muscles of the hind limb were acquired within the field of
view of the MRI images, we were able to measure muscle
volume of this region. The AC consisted of the EDL and TC;
however, it became difficult to discern the boundaries of
each individual muscle in the distal regions so a global
measure of the AC was obtained.
For the T2 analysis, pixel-by-pixel T2 maps were generated
using OsiriX software (v.3.8.1) in three consecutive slices
corresponding to the largest cross-sectional area of the
muscles of interest. Therefore, the mean T2 was the average
of the pixels of the three slices in the belly of the muscle. The
muscle ROIs for the T2 analysis were carefully drawn within
the borders of the muscle to avoid any potential contami-
nation of intermuscular fascia. In addition to comparing the
mean T2 values of each muscle, we also examined the per-
centage of pixels above an individualized ‘‘threshold’’ that
was defined as three standard deviations below the mean T2
value of an ROI manually circled in the subcutaneous fat for
each time point.
Statistical analysis
Mean values from each experimental groupwere compared
using the two-tailed Student’s t test or one-way analysis of
variance (ANOVA) with Student–Newman–Keuls post hoc
analysis, as appropriate. For analysis of MRI data, statistical
analyses were performed using SigmaStat software. As there
was no difference between the left and right legs inmuscle size
and T2 measurements, the two legs were combined into one
group. Statistical analyses were performed using repeated-
measures one-way ANOVA for the longitudinal measures
and two-tailed Student’s t test for comparisons between the
treated and untreated GRMD dogs.
Results
Study design and transgene expression
A total of seven GRMD canines were used in this study that
was designed to determine the efficacy of systemic myostatin
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inhibition via liver-directed gene transfer of an scAAV8 vector
designed to express a secreted dnMSTAT peptide. The AAV8
NAb titer for all canines was < 1:20, which was the lower limit
of detection for the assay used. The scAAV8-dnMSTAT vector
was tested in two normal canines prior to its use in GRMD
canines. One normal canine received 1012 gc/kg vector via
hepatic artery infusion as previously described (Bell et al.,
2011), and one normal canine received 1012 gc/kg vector via
peripheral IV infusion (cephalic vein). Expression levels of
dnMSTAT in canine serum are demonstrated up to 20 weeks
post injection (Fig. 1A). As expression was similar in canines
treated with hepatic artery infusion versus simple, peripheral
IV infusion, IV infusion was used as the injection method for
the remainder of the study.
Treated GRMD canines received 1.7 · 1012 gc/kg vector
(n = 4) via IV infusion, whereas control dogs received no
treatment (n = 3). Euthanasia occurred 13 months post infu-
sion, at *23 months of age. Tissue specificity of the liver-
specific promoter was confirmed by RT-PCR analysis (Fig.
1B), and serum expression of dnMSTAT was confirmed by
western blot (Fig. 1C). Densitometric analysis revealed that
serum dnMSTAT levels were approximately two- to threefold
of baseline (endogenous myostatin propeptide) (Fig. 1D).
Body weight and muscle weight
Following 13 months of systemic myostatin inhibition, the
total body weight of treated GRMD canines was *25%
greater than that of untreated, age-matched controls
( p= 0.05) (Fig. 2A). Individual muscle weights were also
larger by the following percentages in treated versus un-
treated GRMD canines: TC (49%, p= 0.01), EDL (27%,
p = 0.04), gastrocnemius (43%, p< 0.01), and FDS (36%,
p = 0.05) (Fig. 2B). There was no significant difference in the
ratio of these individual muscle weights to total body weight
in treated versus untreated GRMD canines, suggesting that
the increased total body weight was largely a result of in-
creased skeletal muscle mass (Fig. 2C).
Muscle fiber-type and -size analysis
Fiber-typing analysis of the EDL and TC muscles was
performed. Long-term myostatin inhibition in GRMD ca-
nines did not alter the fiber-type composition of either the
EDL (Fig. 3A) or TC (Fig. 3B) muscles. However, further
analysis revealed that long-term myostatin inhibition re-
sulted in increased fiber size selectively in type IIA fibers by
*20% ( p< 0.001); the size of type I fibers was unaffected by
myostatin inhibition (Fig. 3C).
MRI analysis
Representative MRI images are demonstrated in Fig. 4.
The CSAmax of the MG, LG, FDS, TC, and EDL increased
following treatment with liver-targeted systemic myostatin
inhibition in the GRMD dogs (Fig. 5A). The CSAmax of the
lower limb muscles appeared to be either maintained or still
growing after 13 months of treatment, at which time the
CSAmax of the MG, LG, FDS, and TC was significantly
greater in treated versus untreated control GRMD canines
( p< 0.05) (Fig. 5B). Correspondingly, the AC volume in-
creased during the year following treatment, with a similar
percentage increase (20%) as the CSAmax of the TC (18%) and
EDL (25%) (Fig. 5C). At 13 months post treatment, the AC
FIG. 1. Expression of dn-
MSTAT in the canine. (A) Two
different delivery methods
were evaluated in normal ca-
nines: hepatic artery (HA) in-
fusion (n = 1) and IV infusion
via a peripheral vein (n = 1) of
1012 gc/kg scAAV8-dnMSTAT
with liver-specific promoter.
Serum expression of dnMSTAT
is demonstrated up to 20 weeks
by western blot. Serum col-
lected prior to injection was
used as a negative control, and
serum collected from a mouse
injected with the same vector
expressing dnMSTAT was used
as a positive control. Expression
levels were similar following
HA versus IV infusion. (B)
Liver-specific expression of dn-
MSTAT is demonstrated via
RT-PCR in the GRMD canine
(n=4) 13 months following IV
delivery of 1.7·1012 gc/kg
scAAV8-dnMSTAT with liver-
specific promoter. Representative samples (13 months) from untreated GRMD liver and several organs from treated GRMD
canines are shown. (C) Serum expression of dnMSTAT in GRMD canines (n= 3) (one sample was lost due to improper storage)
13 months following IV delivery of 1.7· 1012 gc/kg scAAV8-dnMSTAT with liver-specific promoter. Serum collected prior to
injection was used as a negative control, and serum collected from a mouse injected with the same vector expressing dnMSTAT
was used as a positive control. (D) Densitometric analysis of the MSTAT band in C.
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volume was significantly greater in treated versus untreated
control GRMD canines ( p< 0.05) (Fig. 5D).
The mean T2 relaxation time of the lower hind-limb
muscles was similar in treated versus untreated GRMD ca-
nines in the MG, LG, FDS, and EDL, but was significantly
lower in the TC of treated versus untreated canines ( p< 0.05)
(Fig. 6A). Similarly, the percentage of the muscle region with
elevated T2 pixels was not altered with myostatin inhibition
in the MG, LG, FDS, and EDL, but was lower in the TC of
treated versus untreated GRMD canines ( p < 0.05) (Fig. 6B).
The mean muscle T2 relaxation time in treated dogs tended
to decrease over the 13 months post treatment in the LG
(7 – 4%, p = 0.25), MG (13 – 2%, p = 0.06), FDS (10 – 3%,
p = 0.13), TC (6– 3%, p= 0.16), and EDL (8 – 2%, p= 0.12).
Serum CK, skeletal muscle fibrosis, and liver pathology
Long-term myostatin inhibition resulted in *30% reduc-
tion in serum CK in treated GRMD canines versus untreated
controls ( p< 0.05) (Fig. 7A). In addition, long-term myostatin
inhibition resulted in *20% reduction in fibrosis in the EDL
( p < 0.01) and *25% reduction in fibrosis in the TC
( p < 0.001) in treated GRMD canines versus untreated con-
trols (Fig. 7B). Representative images are shown in Fig. 7C.
Trichrome staining of the liver at 13 months revealed patchy,
acellular areas in both treated and untreated GRMD canines
(Fig. 8A). These areas did not contain significant collagen
content as demonstrated by lack of blue staining. Hematox-
ylin and eosin (H&E) staining of the liver at 13 months also
demonstrated patchy, acellular areas in both treated and
untreated GRMD canines (Fig. 8B). No focal areas of
mononuclear cell infiltration were noted.
Discussion
This is the first report describing the effects of long-term,
systemic myostatin inhibition in a large-animal model of
DMD. scAAV8 designed to express a secreted dnMSTAT
peptide under the control of a liver-specific promoter was
delivered to GRMD canines via simple IV infusion. AAV
serotype 8 was used in this study because it was previously
demonstrated to be capable of achieving efficient hepatic
gene transfer in canines compared with several other sero-
types (Bell et al., 2011). The dominant-negative construct that
was used to inhibit myostatin in this study is a mutated form
of myostatin found in hypermuscular Belgian Blue cattle; it
contains an 11-bp deletion that causes a premature stop in
the C-terminus, leaving only the inhibitory propeptide to be
expressed (Kambadur et al., 1997). In addition, our peptide
has been modified to contain a D76A mutation, which makes
the inhibitory propeptide resistant to proteolysis (Wolfman
et al., 2003). In effect, this construct is a protease-resistant
propeptide that can inhibit endogenous myostatin signaling
by preventing receptor binding (Lee, 2004). We followed
GRMD canines for 13 months following injection of the
dnMSTAT construct and found that systemic myostatin in-
hibition resulted in increased muscle mass in GRMD canines
as assessed by MRI and confirmed at tissue harvest. We also
found that hypertrophy of type IIA fibers was largely re-
sponsible for the increased muscle mass and that reductions
in serum CK and muscle fibrosis were associated with long-
term myostatin inhibition in GRMD.
Although proof-of-principle studies have demonstrated
increased muscle mass following gene transfer of myostatin
inhibitors in healthy NHPs (Kota et al., 2009) and canines
(Qiao et al., 2009), this is the first report describing myostatin
inhibition in a large-animal model of DMD. Similar to what
was observed in the healthy NHP (Kota et al., 2009), in-
creased muscle mass secondary to myostatin inhibition in the
GRMD canine resulted from selective hypertrophy of type II
as opposed to type I fibers. Based on data from mice, the
mechanism underlying this selectivity is likely higher ex-
pression of the activin IIB receptor (myostatin receptor) in
type II fibers (Mendias et al., 2006), although additional
investigation will be necessary to confirm this finding in
large animals.
We also observed that myostatin inhibition was associated
with decreased skeletal muscle fibrosis in GRMD canines at
13 months, a finding that has been previously reported in the
mdx mouse following myostatin inhibition (Qiao et al., 2008)
and genetic ablation of myostatin (Wagner et al., 2002). Evi-
dence suggests that myostatin can regulate skeletal muscle
fibrosis by stimulating proliferation of muscle fibroblasts and
FIG. 2. Effect of myostatin inhibition on body and indi-
vidual skeletal muscle weight in GRMD canines. (A) Total
body weight, (B) the weights of several individual muscles,
and (C) the ratio of individual muscle weight to body weight
are demonstrated 13 months following injection of 1.7 · 1012
gc/kg scAAV8-dnMSTAT with liver-specific promoter (n = 4)
versus untreated, age-matched GRMD controls (n = 3). A
significant increase in total body weight as well as in the
weights of all individual muscles examined was noted.
Gastroc, gastrocnemius. *p < 0.05 vs. control.
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expression of extracellular matrix proteins (Li et al., 2008),
although this may not be the case in the heart (Cohn et al.,
2007). Therefore, myostatin inhibition may attenuate the
skeletal muscle phenotype of GRMD canines by at least two
independent mechanisms: induction of hypertrophy of type
II fibers and blockade of proliferation of muscle fibroblasts.
We also observed reduced serum CK in treated versus
untreated GRMD canines, which is indicative of reduced
muscle damage. We followed treated GRMD canines in this
study with serial MRI. MRI enables sensitive measures of
muscle size over time, and magnetic resonance proton
transverse relaxation time (T2) of muscle has been proposed
as a marker of disease progression and treatment in dys-
trophic muscle (Pacak et al., 2007). T2 is sensitive to a number
of characteristics common in dystrophic disease progression,
including muscle damage (Foley et al., 1999; Mathur et al.,
FIG. 3. Effect of myostatin inhibition on skeletal muscle morphology in GRMD canines. MHC fiber-typing analysis of the
(A) EDL and (B) TC is demonstrated 13 months following injection of 1.7 · 1012 gc/kg scAAV8-dnMSTAT with liver-specific
promoter (n = 4) versus untreated, age-matched GRMD controls (n = 3). Myostatin inhibition did not alter the fiber-type
composition of the EDL or TC. (C) Fiber-size analysis revealed that the increased muscle weight observed in the TC muscle
following myostatin inhibition was secondary to hypertrophy of type IIA fibers only. *p< 0.05 vs. control. (D) Representative
low (10· objective) and high (40 · objective) power images of the TC muscle are demonstrated. Scale bars: 200lm. Color
images available online at www.liebertonline.com/hum
FIG. 4. Representative axial
MRI images from GRMD
canines. Sample ROIs of (A)
distal, (B) mid, and (C) prox-
imal axial slices of the right
lower hind limb of a GRMD
dog. The AC muscle volume
measures were composed of
the EDL and TC. Color ima-
ges available online at www
.liebertonline.com/hum
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2011), fatty tissue infiltration (Kan et al., 2009), and fibrosis
(Loganathan et al., 2006). Reduced damage and associated
edema-like fluid accumulation may have contributed to the
lower T2 in treated versus untreated GRMD canines. Indeed,
we observed that muscle T2 showed a trend to decrease post
treatment in all muscles examined, and there was a signifi-
cant decrease in T2 in the TC of treated versus untreated
animals at the conclusion of the study. Overall, whereas the
mean T2 value reflects a balance between multiple factors,
including fibrosis, edema-like fluid accumulation, and fatty-
tissue accumulation, the lower T2 values in the TC of the
treated GRMD canines seem most consistent with factors
related to reduced susceptibility to injury and the decreased
CK levels observed in this study. A rationale for the other
muscle groups not demonstrating a significantly lower T2 is
difficult to reconcile, but may be due, in part, to the vari-
ability of T2 values among the canines, the relatively small
changes observed, and the small sample size.
We performed this investigation in the GRMD model be-
cause it is the largest available animal model of DMD and is
considered the gold standard for evaluation of novel thera-
peutic interventions for DMD (Wang et al., 2009). The phe-
notype of the GRMD model most closely resembles the
human disease with progressive muscle wasting, degenera-
tion and fibrosis, and shortened life span secondary to re-
spiratory failure or cardiomyopathy (Wang et al., 2009). This
is in contrast to beagle canine X-linked muscular dystrophy
(Shimatsu et al., 2003) and Cavalier King Charles Spaniel
models (Walmsley et al., 2010), which are smaller and easier
to maintain, but which exhibit a less severe phenotype. In
addition, because of the larger size of GRMD canines, the
AAV dose and route of administration derived in this model
should be translatable to patients with DMD without major
up-scaling of vector.
In this study, we evaluated systemic myostatin inhibition
via liver-directed gene transfer following a single IV infu-
sion, a strategy we previously employed in the mdx mouse
using both dnMSTAT (Morine et al., 2010a) and soluble
activin IIB receptor (Morine et al., 2010b). Other gene transfer–
based approaches to myostatin inhibition previously evalu-
ated in large animals include direct intramuscular injection of
vector in healthy NHPs (Kota et al., 2009) and hydrodynamic
limb-vein injection of vector in healthy canines (Qiao et al.,
2009). Although these investigators observed increased mus-
cle mass in the injected muscles, these local delivery tech-
niques would require multiple injections to target every
muscle and muscle group in a DMD patient compared with
the single IV infusion performed in our strategy. Furthermore,
as myostatin inhibition does not prevent turnover of dystro-
phin-deficient muscle fibers, transgene expression would be
lost over time as repair and regeneration occur (Bartoli et al.,
2007; Pacak et al., 2008). This would not be an issue for liver-
directed gene transfer in DMD. In addition, our approach
takes advantage of the highly efficient synthetic machinery of
the liver to secrete the inhibitory peptide into the systemic
circulation.
Other investigators have developed systemic myostatin
inhibition strategies based on injection of anti-myostatin
FIG. 5. MRI analysis of muscle
morphology in GRMD canines.
(A) The CSAmax of MG, LG,
FDS, TC, and EDL at baseline
(month 0) and at monthly time
points post injection of 1.7 · 1012
gc/kg scAAV8-dnMSTAT with
liver-specific promoter for 6
months and at 1 year. Plots
represent mean values, with er-
ror bars omitted for clarity
(n = 4). (B) The CSAmax of
GRMD canines at 13 months
post injection (n= 4) was com-
pared with untreated, age-
matched GRMD controls (n = 3)
(21–25 months of age). *p< 0.05
vs. control. (C) The AC com-
partment volume (TC +EDL) of
treated GRMD canines was also
measured at each time point
(n = 4) and (D) compared with
age-matched, untreated GRMD
controls (n= 3) at 13 months
post injection. *p < 0.05 vs. con-
trol. Values are means – SEM.
MYOSTATIN INHIBITION IN DYSTROPHIC CANINES 1505
antibodies (Bogdanovich et al., 2002; Wagner et al., 2008) and
soluble activin IIB receptor protein (Pistilli et al., 2011).
However, this type of approach would necessitate serial in-
jections based on protein half-life for the duration of a DMD
patient’s life compared with a single IV infusion with our
strategy. In addition, patients would also be at risk for de-
veloping NAbs against these injected foreign proteins. In
contrast, our dnMSTAT peptide is identical to the endoge-
nous propeptide with the exception of a single-point muta-
tion, and even if the resulting single amino acid substitution
has potential for immune activation, evidence suggests that
liver production and secretion may induce tolerance to for-
eign peptides (Mingozzi et al., 2007). Although we did not
assay for the presence of NAbs against dnMSTAT that could
have resulted in submaximal serum levels of dnMSTAT, we
did confirm the presence of serum dnMSTAT at levels ap-
proximately two- to threefold above endogenous propeptide
levels at 13 months post injection in this study. Further
analysis will be necessary to determine the extent, if any, of
the humoral response against dnMSTAT following liver-
directed gene transfer of AAV8-dnMSTAT in this model.
We also performed pathologic analysis of the livers of
treated and untreated GRMD canines at 13 months. We did
not observe any increase in fibrosis in treated livers following
Trichrome staining, nor did we observe any regions of
mononuclear cell infiltration in treated livers following H&E
staining. Although this analysis at 13 months does not allow
us to rule out an earlier immune response, a recent study did
not detect a T-cell response directed against AAV8 capsid
following liver-directed gene transfer in canines (Bell et al.,
2011). Furthermore, as we confirmed expression of
dnMSTAT at 13 months by RT-PCR and western blot, it is
unlikely that a significant T-cell response directed against
hepatocytes expressing dnMSTAT was mounted at an earlier
time point. However, future investigation should be directed
at analyzing the T-cell response at an earlier time point fol-
lowing liver-directed gene transfer of AAV8-dnMSTAT in
this model to support our preliminary findings.
It should be noted, however, that myostatin inhibition is
not a cure for DMD; rather, it is a strategy that can be used to
slow the loss of muscle mass characteristic of this disease.
Stabilization of DMD would require restoration of dystro-
phin expression. Several approaches to achieve this are cur-
rently being evaluated in clinical trials, including exon
skipping (Miyagoe-Suzuki and Takeda, 2010; Moulton and
Moulton, 2010; Partridge, 2010), gene transfer of mini-
dystrophin (Miyagoe-Suzuki and Takeda, 2010), and non-
sense suppression (Finkel, 2010). However, as it is unlikely
that any one of these strategies will result in complete dys-
trophin restoration in every muscle, a combination of
myostatin inhibition and dystrophin restoration approaches
may provide additional benefit in DMD patients. Further-
more, based on observations in normal mice (Lee et al., 2005;
Lee, 2007a), a combination of myostatin inhibition strategies
that target other TGF-b family members in addition to
myostatin [i.e., follistatin, follistatin-like related gene (FLRG),
growth and differentiation factor–associated serum protein-1
(GASP-1), and/or soluble myostatin receptor (Lee, 2004)]
may be more effective than a single-agent approach for in-
creasing muscle mass in DMD. However, our prior experi-
ments suggest that this may not be the case in the mdx
mouse, in which similar benefit was observed with
dnMSTAT (Morine et al., 2010a) and the soluble activin IIB
receptor (Morine et al., 2010b). Additionally, it is unclear if
targeting other TGF-b family members by using the soluble
activin IIB receptor or follistatin will result in side effects not
observed when targeting myostatin alone with dnMSTAT.
Future investigation should be directed at evaluating such
combination approaches in GRMD canines.
In summary, this is the first report describing the effects of
long-term, systemic myostatin inhibition in a large-animal
model of DMD. GRMD canines underwent liver-directed
gene transfer of an scAAV8 vector designed to express a
secreted dnMSTAT peptide, and we observed increased
muscle mass with selective hypertrophy of type IIA fibers in
conjunction with reduced serum CK and muscle fibrosis at
13 months. We believe that the safe, simple, and effective
nature of our liver-directed gene-transfer strategy makes it
an ideal candidate for evaluation as a novel therapeutic
FIG. 6. Analysis of T2 weighted MRI images in GRMD
canines. (A) Mean T2 relaxation time was similar in treated
(n = 4) and untreated (n = 3) GRMD dogs at 13 months in the
MG, LG, EDL, and FDS, whereas T2 relaxation time was
significantly lower in the TC of the treated GRMD dogs
compared with untreated, GRMD controls. *p< 0.05 vs.
control. (B) The percentage of elevated pixels was not sig-
nificantly different at 13 months in treated (n = 4) versus
untreated (n= 3) dogs in the MG, LG, EDL, and FDS; how-
ever, a lower percentage of elevated T2 values was noted in
the TC of treated GRMD dogs versus untreated GRMD
controls. *p< 0.05 vs. control. Values are means – SEM.
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FIG. 7. Effect of myostatin inhibition on serumCK and skeletal muscle fibrosis. (A) SerumCKwasmeasured in GRMD canines at
13months post injection of 1.7·1012 gc/kg scAAV8-dnMSTATwith liver-specific promoter (n=4) and comparedwith age-matched,
untreated GRMD canines (n=3). Serum from a healthy, unaffected canine served as a normal control. Serum CK was significantly
elevated in both treated and untreated GRMD canines compared with normal, but serum CK was elevated to a lesser extent
followingmyostatin inhibition. #p<0.05 vs. normal; *p<0.05 vs. untreatedGRMD. (B) The percentage of fibrotic areawas quantified
followingTrichrome staining in the EDLandTCofGRMDcanines at 13months post injectionof 1.7·1012 gc/kg scAAV8-dnMSTAT
with liver-specific promoter (n=4) and compared with age-matched, untreated GRMD canines (n=3). Fibrosis was significantly
reduced following myostatin inhibition. *p<0.05 vs. control. (C) Representative Trichrome-stained images (10·objective) from the
EDL and TC are presented. Scale bars: 200lm. Color images available online at www.liebertonline.com/hum
FIG. 8. Liver pathology. (A) Tri-
chrome and (B) H&E staining were
performed on liver samples 13
months post injection of 1.7· 1012 gc/
kg scAAV8-dnMSTAT with liver-
specific promoter (n= 4) and com-
pared with age-matched, untreated
GRMDcanines (n= 3). Representative
images are shown. To reduce redun-
dancy, images from a subset of ca-
nines are presented for H&E staining.
Low, 2.5·objective; medium, 10·
objective; high, 40·objective. Scale
bars: 400lm for low, 200lm for
medium and high. Arrow indicates
representative blood vessel (not all
blood vessels are labeled). Color
images available online at www
.liebertonline.com/hum
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approach for DMD patients, perhaps in combination with
dystrophin-restoration approaches.
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